IFO50513 MTA
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | IFO50513 | Cell Name | MTA |
|---|---|---|---|
| Profile | leukemia, NK-like T cell line | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | 58 |
| Identity | available | Tissue for Primary Cancer | hemo-lymphocytic |
| Case history | natural killer (NK)-like T cell leukemia/lymphoma | Metastasis | |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | leukemic cell-like | Character | leukemia, natural killer-like T cell line |
| Classify | tumor | Established by | Emi, N. et al. |
| Registered by | Emi,N. | Regulation for Distribution | |
| Comment | Year | 1999 | |
| Medium | RPMI1640 medium with 10% fetal bovine serum | Methods for Passages | Dilution. Excessive dilution may cause low viability. |
| Cell Number on Passage | 1-2 x 10^5 cells/ml | Race | |
| CO2 Conc. | 5 % | Tissue Sampling | peripheral blasts |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:10222657 | CD4- and CD56-positive T-cell line, MTA, established from natural killer-like T-cell leukemia/lymphoma. Emi N,Abe A,Kasai M,Kohno A,Tanimoto M,Kimura H,Kawashima K,Ito M,Mori N,Saito H Int J Hematol. 1999 Apr;69(3):180-5 |
| Images |
|---|
  |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | IFO50513 | Cell Name | |
|---|---|---|---|
| LOT No. | 03262004 | Lot Specification | distribution |
| Medium | RPMI1640 medium with 10% fetal bovine serum. Use 20% FBS during several days after thawing. | Temperature | 37 C |
| Cell Density at Seeding | 1 x 10^5 | Methods for Passages | dilution |
| Doubling Time | ca. 1.5 days | Cell Number in Vial (cells/1ml) | 1.7 x 10^6 |
| Viability at cell freezing (%) | 83.8 | Antibiotics Used | free |
| Passage Number | P4* | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | Confirmed as human by NP, G6PD (type B), AST. |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | No | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - RPMI1640 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | IFO50513 | Cell Name | MTA |
|---|---|---|---|
| LOT No. | 1126 | Lot Specification | distribution |
| Medium | RPMI1640, 90% ; FBS, 10% | Temperature | 37 C |
| Cell Density at Seeding | 1-2 x 10^5 cells/ml | Methods for Passages | dilution |
| Doubling Time | Cell Number in Vial (cells/1ml) | 1.1 x 10^6 | |
| Viability at cell freezing (%) | 89 | Antibiotics Used | free |
| Passage Number | Unknown (>3 at IFO) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Exoteric Gene | ||
| Medium for Freezing | 10% DMSO, 20% serum (final conc.)-culture medium | CO2 Conc. | |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | IFO50513 | Cell Name | MTA |
|---|---|---|---|
| LOT No. | 02122015 | Lot Specification | distribution |
| Medium | RPMI1640 medium with 10% fetal bovine serum (FBS; GIBCO Cat. # 10091). At early stage of culture after thawing, 20% FBS will be recommended for good growth. | Temperature | 37 C |
| Cell Density at Seeding | 3 x 10^5 cells/mL | Methods for Passages | Dilution (suspension culture). Excessive dilution at passage may cause low viability. |
| Doubling Time | approx. 69 hrs. | Cell Number in Vial (cells/1ml) | 2.2 x 10^6 |
| Viability at cell freezing (%) | 64 | Antibiotics Used | free |
| Passage Number | Unknown (4 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | Confirmed as human by NP, G6PD (type B), MD. |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | D5S818:10,11 D13S317:11 D7S820:10,11 D16S539:9,12 VWA:18,19 TH01:6,7 AM:X TPOX:8,11 CSF1PO:10,11 |
|
| Adhesion | No | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - RPMI1640 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 64 | Additional information |
| Cell No. | IFO50513 | Cell Name | MTA |
|---|---|---|---|
| LOT No. | 01272020 | Lot Specification | distribution |
| Medium | RPMI1640 medium with 10% fetal bovine serum (FBS; Sigma Cat. # 172012). At early stage of culture after thawing, 20% FBS will be recommended for good growth. | Temperature | 37 C |
| Cell Density at Seeding | 6.1 - 7.1 x 10^5 cells/mL | Methods for Passages | Simple dilution (suspension culture). Excessive dilution at passage may cause low viability. |
| Doubling Time | approx. 32 hrs. | Cell Number in Vial (cells/1ml) | 6.4 x 10^6 |
| Viability at cell freezing (%) | 85 | Antibiotics Used | free |
| Passage Number | Unknown (6 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | No | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - RPMI 1640 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 80 | Additional information |